Bacon [1:20% of body surface area. c d The risk of adrenal suppression appears to increase with decreasing age. b (See Systemic Effects under Cautions.) Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol concentrations, and lack of response to corticotropin (ACTH) stimulation. b c d Children also are at greater risk of glucocorticoid insufficiency during and/or after withdrawal of treatment. b c d Intracranial hypertension has occurred in children; manifestations include bulging fontanelles, headaches, and bilateral papilledema. b c d Striae have been reported in children treated inappropriately with topical corticosteroids. b c d Topical corticosteroid therapy in children should be limited to the minimum amount necessary for therapeutic efficacy; chronic topical corticosteroid therapy may interfere with growth and development. b Geriatric Use Response in limited number of patients 65 years of age does not appear to differ from that in younger adults. c d Common Adverse Effects Burning, itching, erythema, irritation,, dryness, papular rash, folliculitis, acneiform eruptions, hypopigmentation c , perioral dermatitis, allergic contact dermatitis, secondary infection, skin atrophy, striae, miliaria. c d Interactions for Alclometasone Dipropionate Specific Drugs and Laboratory Tests Drug or Test Interaction Nitroblue-tetrazolium test for bacterial infection Concurrent use of corticosteroids reportedly may result in false-negative results b Alclometasone Dipropionate Pharmacokinetics Absorption Bioavailability Topically applied alclometasone can be absorbed through normal intact skin. 4 22 b c d Percutaneous penetration varies among individuals 14 and can be altered by using occlusive dressings, 1 4 16 17 d high corticosteroid concentrations, and certain vehicles. 1 15 16 b d Only minimal amounts of topical corticosteroid reach the dermis and subsequently the systemic circulation after application to most normal skin areas; more absorption occurs from the scrotum, axilla, eyelid, face, and scalp than from the forearm, knee, elbow, palm, and sole. b Absorption is markedly increased by loss of the skin s keratin layer and by inflammation and/or diseases of the epidermal barrier (e.g., psoriasis, eczema). 1 16 17 b d Distribution Extent Not known whether topical alclometasone is distributed into milk. c d Elimination Metabolism Once absorbed through the skin, topically applied corticosteroids are metabolized primarily in the liver. 22 b Elimination Route Topical corticosteroids and metabolites are excreted by the kidneys and, to a lesser extent, in bile. 1 22 Stability Storage Topical Cream and ointment: 2 30 C. 1 Some manufacturers state 20 25 C. d Consult product information for specific recommendations. Actions Precise mechanism of action for topical anti-inflammatory activity is unknown; therapeutic benefit in the management of corticosteroid-responsive dermatoses mediated primarily through anti-inflammatory, antipruritic, and vasoconstrictive actions. c d Anti-inflammatory effects may occur through induction of phospholipase A 2 inhibitory proteins (lipocortins); decreased arachidonic acid release from membrane phospholipids. d Decreased arachidonic acid precursors may downregulate biosynthesis of potent inflammatory mediators (e.g., prostaglandins, leukotrienes). d Decreases inflammation by stabilizing leukocyte lysosomal membranes, preventing release of destructive acid hydrolases from leukocytes; inhibiting macrophage accumulation in inflamed areas; reducing leukocyte adhesion to capillary endothelium; reducing capillary wall permeability and edema formation; decreasing complement components; antagonizing histamine activity and release of kinin from substrates; reducing fibroblast proliferation, collagen deposition, and subsequent scar tissue formation; and possibly by other mechanisms as yet unknown. b Advice to Patients Importance of using only as directed, only for the disorder for which it was prescribed, and for no longer than prescribed; avoid contact with the eyes and only apply externally as directed. c d (See Topical Administration under Dosage and Administration.) Importance of not applying on the face, underarms, or groin unless directed by clinician. c d Importance of informing patients that treated areas of the skin should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by a clinician. c d Importance of reporting any local adverse reactions, especially those occurring under occlusive bandage, to a clinician. b c d Importance of informing parents of children not to use in the treatment of diaper dermatitis and not to apply in the diaper area as diapers or plastic pants may constitute occlusive dressings. c d Importance of discontinuing use when control is achieved; importance of contacting clinician if no improvement is seen in 2 weeks. c d Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs. c d Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed. c d Importance of advising patients of other important precautionary information. (See Cautions.) Preparations Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details. Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations. * available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name Alclometasone Dipropionate Routes Dosage Forms Strengths Brand Names Manufacturer Topical Cream 0.05%* Alclometasone Dipropionate Cream (with propylene glycol) Fougera, Taro Aclovate (with propylene glycol) GlaxoSmithKline Ointment 0.05%* Alclometasone Dipropionate Ointment Fougera, Taro Aclovate (with propylene glycol) GlaxoSmithKline AHFS DI Essentials. Copyright 2017, Selected Revisions January 1, 2008. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814. References 1. Glaxo Inc. Aclovate prescribing information. Research Triangle Park, NC; 1986 Sep. 2. Windholz M, ed. The Merck index. 10th ed. Rahway, NJ: Merck & Co, Inc; 1983:34. 3. Cornell RC, Stoughton RB. Correlation of the vasoconstriction assay and clinical activity in psoriasis. Arch Dermatol . 1985; 121:63-7. [PubMed 3881088] 4. Thornfeldt C, Cornell RC, Stoughton RB. The effect of alclometasone dipropionate cream 0.05% on the hypothalamic-pituitary-adrenal axis of normal volunteers. J Int Med Res . 1985; 13:276-80. [PubMed 4054428] 5. Lassus A. Clinical comparison of alclometasone dipropionate cream 0.05% with hydrocortisone butyrate cream 0.1% in the treatment of atopic dermatitis in children. J Int Med Res . 1983; 11:315-9. [PubMed 6357892] 6. Bagatell FK, Barkoff JR, Cohen HJ et al. A multicenter comparison of alclometasone dipropionate cream 0.05% and hydrocortisone cream 1.0% in the treatment of atopic dermatitis. Curr Ther Res . 1983; 33:46-52. 7. Cornell RC. Atrophogenic potential of alclometasone dipropionate ointment 0.05% vs hydrocortisone ointment 1.0%. Curr Ther Res . 1986; 39:260-8. 8. Kalivas J, Kanof NB, Miller OF III et al. A controlled clinical comparison of alclometasone dipropionate cream 0.05% and hydrocortisone cream 1.0% in patients with psoriasis. Curr Ther Res . 1983; 33:408-14. 9. Aggerwal A, Maddin S. Alclometasone dipropionate in psoriasis: a clinical study. J Int Med Res . 1982; 10:414-8. [PubMed 7152079] 10. Frost P. Clinical comparison of alclometasone dipropionate and desonide ointments (0.05%) in the management of psoriasis. J Int Med Res . 1982; 10:375-8. [PubMed 6754511] 11. Lassus A. Alclometasone dipropionate cream 0.05% versus clobetasone butyrate cream 0.05%: a controlled clinical comparison in the treatment of atopic dermatitis in children. Int J Dermatol . 1984; 23:565-6. [PubMed 6389385] 12. Green MJ, Berkenkopf J, Xiomara F et al. Synthesis and structure-activity relationships in a novel series of topically active corticosteroids. J Steroid Biochem . 1979; 11:61-6. [PubMed 491605] 13. Duke EE, Maddin S, Aggerwal A. Alclometasone dipropionate in atopic dermatitis: a clinical study. Curr Ther Res . 1983; 33:769-74. 14. Crespi HG. Topical corticosteroid therapy for children: alclometasone dipropionate cream 0.05%. Clin Ther . 1986; 8:203-10. [PubMed 2938740] 15. Cornell RC, Stoughton RB. The use of topical steroids in psoriasis. Dermatol Clin . 1984; 2:397-409. 16. Cornell RC, Stoughton RB. Use of glucocorticosteroids in psoriasis. Pharmacol Ther . 1980; 2:497-508. 17. Food and Drug Administration. Topical corticosteroids class labeling guideline. (Undated.) Available from: Professional Labeling Branch, Division of Drug Advertising and Labeling, Food and Drug Administration, Rockville, MD. 18. Mobacken H, Hersle K. Alclometasone dipropionate ointment 0.05% versus hydrocortisone ointment 1.0% in children with eczema. Acta Ther . 1986; 12:269-78. 19. Green MJ, Shue HJ, Tiberi R et al. The influence of esterification on the topical antiinflammatory activity of 7 alpha-chloro- and 7 alpha-bromo-16 alpha-methylprednisolones. Arzneimittelforschung . 1980; 30:1618-20. [PubMed 7192095] 20. Lutsky BN, Berkenkopf J, Fernandez X et al. Selective effects of 7 alpha-halogeno substitution on corticosteroid activity: Sch 22219 and Sch 23409. Arzneimittelforschung . 1979; 29:992-8. [PubMed 583002] 21. Lutsky BN, Berkenkopf J, Fernandez X et al. A novel class of potent topical antiinflammatory agents: 17-benzoylated, 7 alpha-halogeno substituted corticosteroids. Arzneimittelforschung . 1979; 29:1662-7. [PubMed 543873] 22. Vonderweidt J (Glaxo, Research Triangle Park, NC): Personal communication; 1987 Apr 15. 23. Reviewers comments (personal observations); 1987 Apr. 24. Tokiwa T, Oyama T, Kimura S et al. [Studies on the primary dermal irritation, ocular mucosa irritation and local anaesthetic effect of alclometasone dipropionate (ADP)]. (Japanese; with English abstract.) Oyo Yakuri . 1986; 32:937-43. 25. Fujii K, Uda F, Yamamoto K. [Phototoxicity and photosensitivity tests of alclometasone dipropionate (ADP).] (Japanese; with English abstract.) Oyo Yakuri . 1986; 32:945-51. 26. Hasegawa T, Tujita K, Fujino A et al. [Immunogenicity study on alclometasone dipropionate (ADP)]. (Japanese; with English abstract.) Oyo Yakuri . 1986; 32:953-60. 27. Sills J (Schering, Kenilworth, NJ): Personal communication; 1987 May 28. 28. Lechner D (Schering, Kenilworth, NJ): Personal communication; 1987 June 3. a. AHFS drug information 2007. McEvoy GK, ed. Alclometasone dipropionate. Bethesda, MD: American Society of Health-Systems Pharmacists; 2007: 3525 6. b. AHFS drug information 2007 McEvoy GK, ed. Topical corticosteroids general statement. Bethesda, MD: American Society of Health-System Pharmacists; 2007:3423 5. c. GlaxoSmithKline. Aclovate (alclometasone dipropionate) cream and ointment 0.05% prescribing information. Pittsburgh, PA; 2002 Aug. d. Taro Pharmaceuticals. Alclometasone dipropionate ointment USP, 0.05% prescribing information. Hawthorne, NY; 2004 Jul. Next Interactions Print this page Add to My Med List More about alclometasone topical Side Effects During Pregnancy or Breastfeeding Dosage Information Drug Interactions Support Group Pricing & Coupons En Español 2 Reviews Add your own review/rating Drug class: topical steroids Consumer resources Alclometasone topical Alclometasone Professional resources Alclometasone (FDA) Alclometasone Ointment (FDA) Alclometasone (Wolters Kluwer) Other brands: Aclovate Related treatment guides Eczema Atopic Dermatitis Dermatitis Psoriasis]} FEATURED: CAR-T Cell Therapy Overview Mechanism of Action KTE-C19 Studies KTE-C19 Cancer Targets Adverse Events Manufacturing Drug Status Rx Availability Prescription only C Pregnancy Category Risk cannot be ruled out N/A CSA Schedule Not a controlled drug Approval History Drug history at FDA Manufacturers Sandoz Inc. Taro Pharmaceuticals U.S.A., Inc. Glenmark Pharmaceuticals Inc., USA Drug Class Topical steroids Related Drugs Eczema prednisone , fluticasone topical , triamcinolone topical , hydrocortisone topical , dexamethasone , clobetasol topical , More... Atopic Dermatitis prednisone , fluticasone topical , triamcinolone topical , hydrocortisone topical , dexamethasone , methylprednisolone , More... Dermatitis fluticasone topical , triamcinolone , hydrocortisone topical , prednisolone , clobetasol topical , More... Psoriasis Humira , methotrexate , cyclosporine , Remicade , adalimumab , infliximab , More... Alclometasone topical Rating 2 User Reviews 8.7 /10 2 User Reviews 8.7 Rate it!} } is well known
and ridicule Alclometasone Dipropionate that i'm wondering
EmoticonEmoticon